Venetoclax Duration (14 Vs. 21 Vs. 28 Days) in Combination with Hypomethylating Agent in Newly Diagnosed Acute Myeloid Leukemia: Comparative Analysis of Response, Toxicity, and Survival.
American journal of hematology（2023）
摘要
Overall survival and response rates of 270 patients with newly diagnosed acute myeloid leukemia receiving venetoclax (Ven) plus hypomethylating agent, stratified by Ven dosing schedule (Cycle 1 Ven 14 vs. 21 vs. 28 days).
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要